NasdaqCM - Nasdaq Real Time Price USD

Palvella Therapeutics, Inc. (PVLA)

25.40
+1.91
+(8.13%)
At close: June 6 at 4:00:00 PM EDT
24.91
-0.49
(-1.93%)
After hours: June 6 at 5:24:26 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for PVLA

Recent News: PVLA

View More
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer
GlobeNewswire 11 days ago

Palvella Therapeutics Inc (PVLA) Q1 2025 Earnings Call Highlights: Strong Clinical Progress ...
GuruFocus.com 22 days ago
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire 23 days ago
Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
GlobeNewswire 30 days ago
Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025
GlobeNewswire last month
Why Palvella Therapeutics, Inc. (PVLA) is Surging in 2025

Why Palvella Therapeutics, Inc. (PVLA) is Surging in 2025
Insider Monkey last month
One Palvella Therapeutics Insider Raised Their Stake In The Previous Year

One Palvella Therapeutics Insider Raised Their Stake In The Previous Year
Simply Wall St. last month
Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology
GlobeNewswire last month
Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
GlobeNewswire last month
Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology

Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology
GlobeNewswire last month
Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
GlobeNewswire 2 months ago
View More

Related Tickers

THRD Third Harmonic Bio, Inc.
5.29
0.00%
 
SYRE Spyre Therapeutics, Inc.
16.97
+2.11%
 
CNTA Centessa Pharmaceuticals plc
11.92
+0.51%
 
GHRS GH Research PLC
12.50
-0.87%
 
FBRX Forte Biosciences, Inc.
11.32
+9.37%
 
TRML Tourmaline Bio, Inc.
19.27
+2.01%
 
KLRS Kalaris Therapeutics, Inc.
3.3000
+6.11%
 
CGEM Cullinan Therapeutics, Inc.
9.08
+3.89%
 
LXEO Lexeo Therapeutics, Inc.
3.8800
+18.65%
 
XNCR Xencor, Inc.
9.65
+5.81%